BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 16210564)

  • 1. A novel inhibitor of oxidosqualene:lanosterol cyclase inhibits very low-density lipoprotein apolipoprotein B100 (apoB100) production and enhances low-density lipoprotein apoB100 catabolism through marked reduction in hepatic cholesterol content.
    Telford DE; Lipson SM; Barrett PH; Sutherland BG; Edwards JY; Aebi JD; Dehmlow H; Morand OH; Huff MW
    Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2608-14. PubMed ID: 16210564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs.
    Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
    Endocrinology; 1999 Nov; 140(11):5293-302. PubMed ID: 10537160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs.
    Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
    Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2589-600. PubMed ID: 9409231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced synthesis of the oxysterol 24(S),25-epoxycholesterol in macrophages by inhibitors of 2,3-oxidosqualene:lanosterol cyclase: a novel mechanism for the attenuation of foam cell formation.
    Rowe AH; Argmann CA; Edwards JY; Sawyez CG; Morand OH; Hegele RA; Huff MW
    Circ Res; 2003 Oct; 93(8):717-25. PubMed ID: 14512442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of cholesterol esterification by DuP 128 decreases hepatic apolipoprotein B secretion in vivo: effect of dietary fat and cholesterol.
    Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Huff MW
    Biochim Biophys Acta; 1998 Jul; 1393(1):63-79. PubMed ID: 9714740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ro 48-8.071, a new 2,3-oxidosqualene:lanosterol cyclase inhibitor lowering plasma cholesterol in hamsters, squirrel monkeys, and minipigs: comparison to simvastatin.
    Morand OH; Aebi JD; Dehmlow H; Ji YH; Gains N; Lengsfeld H; Himber J
    J Lipid Res; 1997 Feb; 38(2):373-90. PubMed ID: 9162756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans.
    Millar JS; Brousseau ME; Diffenderfer MR; Barrett PH; Welty FK; Faruqi A; Wolfe ML; Nartsupha C; Digenio AG; Mancuso JP; Dolnikowski GG; Schaefer EJ; Rader DJ
    Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):1350-6. PubMed ID: 16574893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of ACAT by avasimibe decreases both VLDL and LDL apolipoprotein B production in miniature pigs.
    Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
    J Lipid Res; 1999 Jul; 40(7):1317-27. PubMed ID: 10393217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the apical sodium-dependent bile acid transporter reduces LDL cholesterol and apoB by enhanced plasma clearance of LDL apoB.
    Huff MW; Telford DE; Edwards JY; Burnett JR; Barrett PH; Rapp SR; Napawan N; Keller BT
    Arterioscler Thromb Vasc Biol; 2002 Nov; 22(11):1884-91. PubMed ID: 12426220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of hepatic ACAT decreases ApoB secretion in miniature pigs fed a cholesterol-free diet.
    Huff MW; Telford DE; Barrett PH; Billheimer JT; Gillies PJ
    Arterioscler Thromb; 1994 Sep; 14(9):1498-508. PubMed ID: 8068612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of a novel 2,3-oxidosqualene cyclase inhibitor on cholesterol biosynthesis and lipid metabolism in vivo.
    Eisele B; Budzinski R; Müller P; Maier R; Mark M
    J Lipid Res; 1997 Mar; 38(3):564-75. PubMed ID: 9101437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased VLDL in nephrotic patients results from a decreased catabolism while increased LDL results from increased synthesis.
    de Sain-van der Velden MG; Kaysen GA; Barrett HA; Stellaard F; Gadellaa MM; Voorbij HA; Reijngoud DJ; Rabelink TJ
    Kidney Int; 1998 Apr; 53(4):994-1001. PubMed ID: 9551409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of stigmastanyl-phosphocholine (Ro 16-6532) and lovastatin on lipid and lipoprotein levels and lipoprotein metabolism in the hamster on different diets.
    Himber J; Missano B; Rudling M; Hennes U; Kempen HJ
    J Lipid Res; 1995 Jul; 36(7):1567-85. PubMed ID: 7595080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down-regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase mRNA levels and synthesis in syrian hamster C100 cells by the oxidosqualene cyclase inhibitor [4'-(6-allyl-ethyl-amino-hexyloxy)-2'-fluoro-phenyl]-(4-bromophenyl)-me thanone (Ro 48-8071): comparison to simvastatin.
    Peffley DM; Gayen AK; Morand OH
    Biochem Pharmacol; 1998 Aug; 56(4):439-49. PubMed ID: 9763219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of both the apical sodium-dependent bile acid transporter and HMG-CoA reductase markedly enhances the clearance of LDL apoB.
    Telford DE; Edwards JY; Lipson SM; Sutherland B; Barrett PH; Burnett JR; Krul ES; Keller BT; Huff MW
    J Lipid Res; 2003 May; 44(5):943-52. PubMed ID: 12562847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of cholesterogenesis decreases hepatic secretion of apoB-100 in normolipidemic subjects.
    Watts GF; Naoumova RP; Kelly JM; Riches FM; Croft KD; Thompson GR
    Am J Physiol; 1997 Sep; 273(3 Pt 1):E462-70. PubMed ID: 9316434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin.
    Telford DE; Sutherland BG; Edwards JY; Andrews JD; Barrett PH; Huff MW
    J Lipid Res; 2007 Mar; 48(3):699-708. PubMed ID: 17130282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lovastatin decreases de novo cholesterol synthesis and LDL Apo B-100 production rates in combined-hyperlipidemic males.
    Cuchel M; Schaefer EJ; Millar JS; Jones PJ; Dolnikowski GG; Vergani C; Lichtenstein AH
    Arterioscler Thromb Vasc Biol; 1997 Oct; 17(10):1910-7. PubMed ID: 9351353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carbamazepine increases atherogenic lipoproteins: mechanism of action in male adults.
    Brämswig S; Kerksiek A; Sudhop T; Luers C; Von Bergmann K; Berthold HK
    Am J Physiol Heart Circ Physiol; 2002 Feb; 282(2):H704-16. PubMed ID: 11788421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipoprotein lipases, lipoprotein density gradient profile and LDL receptor activity in miniature pigs fed fish oil and corn oil.
    Huff MW; Telford DE; Edmonds BW; McDonald CG; Evans AJ
    Biochim Biophys Acta; 1993 Dec; 1210(1):113-22. PubMed ID: 8257713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.